Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 225

Similar articles for PubMed (Select 21477947)

1.

Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.

Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e423-9. doi: 10.1016/j.ijrobp.2011.01.048. Epub 2011 Apr 7.

PMID:
21477947
2.
3.

Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.

Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):898-905. doi: 10.1016/j.ijrobp.2010.11.003. Epub 2011 Jan 14.

PMID:
21237581
4.

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. doi: 10.1016/j.ijrobp.2009.01.048. Epub .

PMID:
19395192
5.

Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.

Koontz BF, Mouraviev V, Johnson JL, Mayes J, Chen SH, Wong TZ, Anscher MS, Sun L, Moul J, Polascik TJ.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):358-61. doi: 10.1016/j.ijrobp.2007.10.020. Epub 2007 Dec 31.

PMID:
18164863
6.

Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.

Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):85-92. doi: 10.1016/j.ijrobp.2007.12.041. Epub 2008 Mar 20.

PMID:
18355982
7.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18.

PMID:
20171807
8.

The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.

Proaño JM, Sodee DB, Resnick MI, Einstein DB.

J Urol. 2006 May;175(5):1668-72.

PMID:
16600726
10.

Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.

Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, Faulhaber PF, Bodner D.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):29-34. doi: 10.1016/j.ijrobp.2010.05.053. Epub 2010 Oct 18.

PMID:
20961696
11.

Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.

Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escudé L.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):50-7. doi: 10.1016/j.ijrobp.2009.07.1689. Epub 2009 Nov 10.

PMID:
19910135
12.

A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.

Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):400-8.

PMID:
15667959
13.

Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204-12. doi: 10.1016/j.ijrobp.2010.10.009. Epub 2010 Dec 16.

PMID:
21167653
14.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

15.

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.

Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1013-20. doi: 10.1016/j.ijrobp.2008.12.047. Epub 2009 Apr 20.

PMID:
19386427
16.

Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.

Valeriani M, Carnevale A, Osti MF, Minniti G, De Sanctis V, Agolli L, Bracci S, Enrici RM.

Tumori. 2013 Jul-Aug;99(4):474-9. doi: 10.1700/1361.15097.

PMID:
24326835
17.

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.

Petronis JD, Regan F, Lin K.

Clin Nucl Med. 1998 Oct;23(10):672-7.

PMID:
9790041
18.

Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.

McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):413-20. doi: 10.1016/j.ijrobp.2008.10.050. Epub 2009 Apr 11.

PMID:
19362783
19.

Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

Rosenthal SA, Haseman MK, Polascik TJ.

Tech Urol. 2001 Mar;7(1):27-37. Review.

PMID:
11272670
20.

Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.

Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8.

PMID:
19427741
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk